共有 50 笔近期内部人交易记录记录，涉及 Soleno Therapeutics, Inc. (SLNO), 包括 23 笔买入 和 22 笔卖出. 内部人买入总额为 $21.22M 内部人卖出总额为 $129.87M.
近期活跃的重要内部人包括 Manning Meredith, Huang Michael F., Fulk Jennifer. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — SLNO
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-27 |
Manning Meredith |
Chief Commercial Officer |
知情卖出 |
558 |
$31.72 |
$17.7K |
64,507 |
| 2026-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
知情卖出 |
488 |
$31.72 |
$15.48K |
39,823 |
| 2026-03-02 |
Fulk Jennifer |
Officer |
未知 |
- |
- |
- |
- |
| 2026-03-02 |
Fulk Jennifer |
Chief Financial Officer |
限制性股票授予 (RSU) |
39,200 |
- |
- |
39,200 |
| 2026-01-21 |
Mackaness James H |
Chief Financial Officer |
限制性股票授予 (RSU) |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
限制性股票授予 (RSU) |
131,400 |
$43.65 |
$5.74M |
131,400 |
| 2026-01-21 |
Yen Kristen |
See Remarks |
限制性股票授予 (RSU) |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Manning Meredith |
Chief Commercial Officer |
限制性股票授予 (RSU) |
32,800 |
$43.65 |
$1.43M |
32,800 |
| 2026-01-21 |
Hirano Patricia C |
See Remarks |
限制性股票授予 (RSU) |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2026-01-21 |
Norrett Kevin |
Chief Business Officer |
限制性股票授予 (RSU) |
4,000 |
$43.65 |
$174.6K |
4,000 |
| 2026-01-21 |
Joshi Manher |
Chief Development Officer |
限制性股票授予 (RSU) |
4,700 |
$43.65 |
$205.16K |
4,700 |
| 2026-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
限制性股票授予 (RSU) |
11,900 |
$43.65 |
$519.44K |
11,900 |
| 2025-12-15 |
Mackaness James H |
Chief Financial Officer |
RSU 预扣税 |
2,013 |
$49.95 |
$100.55K |
103,163 |
| 2025-12-15 |
Anish Bhatnagar |
Chief Executive Officer |
赠与（送出） |
100,000 |
- |
- |
469,456 |
| 2025-12-15 |
Yen Kristen |
See Remarks |
RSU 预扣税 |
904 |
$49.95 |
$45.15K |
27,239 |
| 2025-12-15 |
Manning Meredith |
Chief Commercial Officer |
RSU 预扣税 |
1,922 |
$49.95 |
$96K |
43,429 |
| 2025-12-15 |
Hirano Patricia C |
See Remarks |
RSU 预扣税 |
904 |
$49.95 |
$45.15K |
12,302 |
| 2025-12-15 |
Huang Michael F. |
Sr. VP of Clinical Development |
RSU 预扣税 |
812 |
$49.95 |
$40.56K |
36,005 |
| 2025-11-17 |
Norrett Kevin |
Officer |
未知 |
- |
- |
- |
- |
| 2025-11-17 |
Norrett Kevin |
Chief Business Officer |
限制性股票授予 (RSU) |
14,286 |
- |
- |
14,286 |
| 2025-11-10 |
Joshi Manher |
Officer |
未知 |
- |
- |
- |
- |
| 2025-11-10 |
Joshi Manher |
Chief Development Officer |
限制性股票授予 (RSU) |
16,071 |
- |
- |
16,071 |
| 2025-10-13 |
Hahn Mark W |
Officer |
未知 |
- |
- |
- |
- |
| 2025-10-13 |
Hahn Mark W |
Director |
限制性股票授予 (RSU) |
10,046 |
- |
- |
10,046 |
| 2025-07-01 |
Hirano Patricia C |
See Remarks |
知情卖出 |
3,830 |
$82.76 |
$316.97K |
13,206 |
| 2025-06-24 |
Hirano Patricia C |
See Remarks |
期权行权（卖出） |
266 |
$44.25 |
$11.77K |
- |
| 2025-06-05 |
Harris William G |
Director |
限制性股票授予 (RSU) |
3,991 |
- |
- |
19,392 |
| 2025-06-05 |
Pauls Matthew |
Director |
限制性股票授予 (RSU) |
3,991 |
- |
- |
10,491 |
| 2025-06-05 |
Bir Dawn Carter |
Director |
限制性股票授予 (RSU) |
3,991 |
- |
- |
16,991 |
| 2025-06-05 |
Volck Birgitte |
Director |
限制性股票授予 (RSU) |
3,991 |
- |
- |
17,536 |
| 2025-06-05 |
Sinclair Andrew |
Director |
限制性股票授予 (RSU) |
3,991 |
- |
- |
10,491 |
| 2025-04-01 |
Hirano Patricia C |
See Remarks |
知情卖出 |
3,782 |
$70.11 |
$265.16K |
27,036 |
| 2025-03-28 |
Vivo Opportunity, Llc |
10 Percent Owner |
知情卖出 |
333,557 |
$70.60 |
$23.55M |
4,458,294 |
| 2025-03-28 |
Pauls Matthew |
Director |
知情卖出 |
5,937 |
$71.55 |
$424.8K |
6,500 |
| 2025-03-28 |
Hirano Patricia C |
See Remarks |
期权行权（卖出） |
2,691 |
$33.60 |
$90.42K |
18,842 |
| 2025-03-27 |
Vivo Opportunity, Llc |
10 Percent Owner |
知情卖出 |
1,100,000 |
$67.80 |
$74.58M |
4,791,851 |
| 2025-03-27 |
Mackaness James H |
Chief Financial Officer |
期权行权（卖出） |
5,000 |
$2.60 |
$12.98K |
- |
| 2025-03-27 |
Anish Bhatnagar |
Chief Executive Officer |
期权行权（卖出） |
16,666 |
$25.05 |
$417.48K |
- |
| 2025-03-27 |
Yen Kristen |
See Remarks |
期权行权（卖出） |
4,888 |
$5.10 |
$24.93K |
2,445 |
| 2025-03-27 |
Manning Meredith |
Chief Commercial Officer |
知情卖出 |
37,000 |
$67.04 |
$2.48M |
45,351 |
| 2025-03-27 |
Hirano Patricia C |
See Remarks |
期权行权（卖出） |
6,000 |
$24.00 |
$144K |
- |
| 2025-03-27 |
Huang Michael F. |
Sr. VP of Clinical Development |
知情卖出 |
10,000 |
$70.03 |
$700.33K |
36,817 |
| 2025-03-26 |
Vivo Opportunity, Llc |
10 Percent Owner |
知情卖出 |
400,000 |
$65.80 |
$26.32M |
5,891,851 |
| 2025-01-21 |
Mackaness James H |
Chief Financial Officer |
限制性股票授予 (RSU) |
31,000 |
$49.17 |
$1.52M |
31,000 |
| 2025-01-21 |
Anish Bhatnagar |
Chief Executive Officer |
限制性股票授予 (RSU) |
115,600 |
$49.17 |
$5.68M |
115,600 |
| 2025-01-21 |
Yen Kristen |
See Remarks |
限制性股票授予 (RSU) |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Manning Meredith |
Chief Commercial Officer |
限制性股票授予 (RSU) |
29,200 |
$49.17 |
$1.44M |
29,200 |
| 2025-01-21 |
Hirano Patricia C |
See Remarks |
限制性股票授予 (RSU) |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-21 |
Huang Michael F. |
Sr. VP of Clinical Development |
限制性股票授予 (RSU) |
13,800 |
$49.17 |
$678.55K |
13,800 |
| 2025-01-03 |
Mackaness James H |
Chief Financial Officer |
知情卖出 |
3,791 |
$46.18 |
$175.05K |
111,298 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
